Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Masatoshi Kudo; Kenta Motomura; Yoshiyuki Wada; Yoshitaka Inaba; Yasunari Sakamoto; Masayuki Kurosaki; Yoshiko Umeyama; Yoichi Kamei; Junichiro Yoshimitsu; Yosuke Fujii; Mana Aizawa; Paul B. Robbins; Junji Furuse

doi:10.1159/000514420

Shared by

Masatoshi Kudo

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Article 2021 en

Authors

Masatoshi Kudo
KM
Kenta Motomura
YW
Yoshiyuki Wada

Abstract

1 min read

Treatment with avelumab plus axitinib was associated with a manageable toxicity profile and showed antitumor activity in patients with aHCC.

Related publications

Dataset

Supplementary Material for: Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, Yoshitaka Inaba, Yasunari Sakamoto, Masayuki Kurosaki, Yoshiko Umeyama, Yoichi Kamei, J. Yoshimitsu, Yoshiro Fujii, Mamoru Aizawa, Paul B. Robbins, Junji Furuse

Article2019

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).

Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, Yoshitaka Inaba, Yasunari Sakamoto, Masayuki Kurosaki, Yoshiko Umeyama, Yoichi Kamei, Junichiro Yoshimitsu, Yosuke Fujii, Mana Aizawa, Paul B. Robbins, Junji Furuse

Article2005

The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma

Aristotle Bamias, Lia A. Moulopoulos, Aggelos Koutras, Gerasimos Aravantinos, George Fountzilas, D. Pectasides, Efstathios Kastritis, D. Gika, Dimosthenis Skarlos, Helena Linardou, Haralabos P. Kalofonos, Meletios A Dimopoulos

Dataset

Supplementary Material for: Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study

Masatoshi Kudo, Yoon‐Koo Kang, J.-W. Park, Shukui Qin, Yoshitaka Inaba, Éric Assenat, Yoshiko Umeyama, M.J. Lechuga, Olga Valota, Yoshiro Fujii, Jean-François Martini, James A. Williams, Shuntaro Obi

Article2022

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.

Ivan Borbath, Jean‐Luc Van Laethem, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Francesca Bergamo, Per Stål, Debashis Sarker, Daniel H. Palmer, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Abby B. Siegel, Ken Hatogai, Anran Wang, Arndt Vogel

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Abstract

Discussion(0)

Related publications

Supplementary Material for: Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).

The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma

Supplementary Material for: Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.